HTA17 - Cost-Effectiveness Analysis of Capivasertib Plus Fulvestrant in Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2-) Negative Advanced Breast Cancer: A US Payer Perspective

SA1 - Methods for Incorporating Non-Randomized Evidence From Single-Arm Trials Into Network Meta-Analysis (NMA): A Case Study in Recurrent/Metastatic Head and Neck Cancer (R/M-HNSCC)

EE47 - Cost Per Recurrence-Free Survivor (CPRS) and Cost Per Recurrence-Free Life Month (CPRLM) of Adjuvant Nivolumab (NIVO) Versus Pembrolizumab (PEMBRO) Among Patients With Resected Stage IIB/IIC Melanoma

MSR23 - Optimizing Regression Models for Patient-Level Utility Scores: A Case Study on Addressing Ceiling Effects in EQ-5D Data from the MYR301 Clinical Trial

CO82 - Bayesian Pan-Tumor Multilevel Meta-Regression: An Unanchored Indirect Treatment Comparison (ITC) of Adagrasib Versus Sotorasib in Previously Treated KRASG12C-mutated Advanced/Metastatic Solid Tumors

EE123 - Cost-Effectiveness of the Brexu-Cel in Relapsed/Refractory Mantle Cell Lymphoma and B-Cell Acute Lymphoblastic Leukemia: A Systematic Review

EE157 - Assessing the Cost-Effectiveness of Sodium Phenylbutyrate/Taurursodiol and Oral Edaravone in the Treatment of Amyotrophic Lateral Sclerosis

PT35 - Cost-Effectiveness Analysis of Nivolumab Versus Docetaxel for the Treatment of Advanced Nonsquamous NSCLC Including PD-L1 Testing in the United States

HSD73 - Neoadjuvant & Adjuvant Therapy for Early-Stage/Resectable Non-Small Cell Lung Cancer (NSCLC): Physician Practices, Therapy Choice, and Challenges Among US Oncologists

PT33 - Cost-Effectiveness of Cemiplimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy As the First-Line Treatment for Advanced Non-Small Cell Lung Cancer: A Preliminary Study

HSD65 - Influence of Research Findings and Systems on Minimal Residual Disease (MRD) Testing and FLT3 Inhibitor Maintenance Prescribing Behavior Post-Transplant for Patients with Acute Myeloid Leukemia (AML) of U.S. Oncologists

EE395 - Cost-Effectiveness Analysis of Nivolumab Plus Relatlimab (NIVO+RELA) Versus Current Standard of Care (SOC) for Patients with Unresectable or Metastatic Melanoma in Canada

EE388 - Economic Evaluation and Budget Impact of Brigatinib Versus Other ALK-Inhibitors for First-Line ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Treatment in the Brazilian Private Healthcare System

EE411 - Cost-Effectiveness of Venetoclax in Combination with Azacitidine in Unfit Patients With Previously Untreated Acute Myeloid Leukemia in China

CO166 - Patient Reported Outcomes of Vonoprazan in Chinese Reflux Esophagitis Patients: A Prospective Real-World Study